Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2022 | ESMO 2022: Highlights from the Presidential Symposium

Solange Peters, MD, PhD, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland, provides an overview of key trials presented during the Presidential Symposium of the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France. These include a talk on air pollution induced non-small cell lung cancer in never smokers, the results of the Phase III DeFi trial (NCT03785964) of randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors as well as findings of a Phase III study (NCT02278887) evaluating tumor-infiltrating lymphocytes (TILs) in patients with advanced melanoma. This interview took place at the ESMO 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.